Please login to the form below

Not currently logged in
Email:
Password:

migraine

This page shows the latest migraine news and features for those working in and with pharma, biotech and healthcare.

AbbVie submits migraine prevention drug to EMA for marketing authorisation

AbbVie submits migraine prevention drug to EMA for marketing authorisation

Atogepant is an orally administered, CGRP receptor antagonist developed for the prevention of migraines. ... Studies have shown that CGRP levels are elevated during migraine attacks, with selective CGRP receptor antagonists demonstrating clinical benefit

Latest news

  • Pfizer to acquire Biohaven in deal worth over $11bn Pfizer to acquire Biohaven in deal worth over $11bn

    The deal will expand Pfizer’s Internal Medicine pipeline. Pfizer has announced it will acquire Biohaven Pharmaceutical, the makers of a US-approved dual-acting migraine therapy. ... The therapy is approved for both acute treatment and episodic

  • AbbVie shares positive phase 3 results for migraine drug Qulipta AbbVie shares positive phase 3 results for migraine drug Qulipta

    migraines – which has shown that a once-daily 60mg dose as well as a twice-daily 30mg dose of Qulipta works in preventing chronic migraine. ... for more than three months, which on at least eight days per month has features of migraine headache.

  • Pfizer snaps up Biohaven’s migraine drug for $1.24bn Pfizer snaps up Biohaven’s migraine drug for $1.24bn

    Pfizer will sell the migraine drug outside the US and will also gain the rights to a second drug. ... Neuroscience specialist Biohaven Pharmaceuticals has teamed up with Pfizer to commercialise its recently launched migraine drug Nurtec ODT (rimegepant)

  • Eli Lilly focuses on 2022 launches as revenues climb by 18% Eli Lilly focuses on 2022 launches as revenues climb by 18%

    Diabetes medicine Trulicity (dulaglutide), immunology blockbuster Taltz (ixekizumab), breast cancer therapy Verzenio (abemaciclib) and migraine prevention antibody Emgality (galcanezumab-gnlm) each saw revenues rise by more than 30% year on year.

  • Lundbeck drops Parkinson’s drug acquired in €905m deal Lundbeck drops Parkinson’s drug acquired in €905m deal

    It has added to its pipeline under Dunsire with a $1.95bn takeover of Alder Biopharma, adding migraine prevention therapy Vyepti (eptinezumab) – which is launching in competition with rival drugs from

More from news
Approximately 30 fully matching, plus 149 partially matching documents found.

Latest Intelligence

  • What Hemingway got right about patient communications What Hemingway got right about patient communications

    as multiple sclerosis and migraine, to monitor their health and track the success of their medication. ... To create Rain Free Days, we worked closely with staff and patients at the National Migraine Centre and Prof Zameel Cader at The John Radcliffe

  • Cortellis Drugs to Watch in 2020 report Cortellis Drugs to Watch in 2020 report

    Eli Lilly/Dong Pharmaceuticals’ 5-HT1f agonist Reyvow was approved in the US in October 2019 as the first acute treatment for migraine in 20 years. ... Allergan’s Ubrelvy is the only other oral CGRP antagonist approved for acute migraine, which

  • 20 for 2020 – Five pharma companies to watch 20 for 2020 – Five pharma companies to watch

    pipeline. He argues, however, that layering in products like Allergan’s blockbuster wrinkle and migraine treatment Botox will improve near-term cashflow and help fund the roll-out of a new ... year. Botox is facing tougher competition in the market

  • Key considerations for disease- modifying Parkinson’s disease trials Key considerations for disease- modifying Parkinson’s disease trials

    Published adherence in migraine-prophylaxis (as a comparable indication) indicates 92.6% adherent at one month, 40.7% at two months, 30.9% at three months, 24.8% at four months,

  • Deal Watch January 2018

    III CGRP antibody for the treatment of migraine.

More from intelligence
Approximately 1 fully matching, plus 26 partially matching documents found.

Latest appointments

More from appointments
Approximately 0 fully matching, plus 3 partially matching documents found.

Latest from PMHub

  • Who cares… about great healthcare creative? Who cares… about great healthcare creative?

    the link between Covid-19 and sepsis) and Rain Free Days, an app we created to help migraine sufferers track and manage their symptoms.

  • How to make sure your adverts for clinical trials are compliant How to make sure your adverts for clinical trials are compliant

    Click here to find out who can take part. Take part in this clinical trial for a new migraine treatment that eases the symptoms of migraines. ... A clinical trial is exploring a potential treatment for migraines. Click here to find out who can take part

  • #DemandDiversity: The science behind diversity #DemandDiversity: The science behind diversity

    Women suffer from migraines three times as often as men.

  • Migraine-friendly colours for the home Migraine-friendly colours for the home

    You may not realise it, but colour impacts migraines. 11 London worked with Teva Pharmaceuticals UK, Dulux Paints and the National Migraine Centre to test this theory among 1, 200 migraine ... Many factors can trigger a migraine - even something as

  • Infographic

    Migraine market snapshot. Research Partnership’s migraine market snapshot offers an introduction to the real world patient data collected by their Therapy Watch migraine study.

More from PMHub
Approximately 1 fully matching, plus 10 partially matching documents found.

Subscribe to our email news alerts

Featured jobs

PMHub

Add my company
Medscape Education Global

Medscape delivers dynamic, innovative education to optimize learner engagement and patient outcomes worldwide....

Latest intelligence

The communication challenge of helping he next generation to be healthier
As the pressure on the health service increases the health of the next generation is vital for everyone. How do we show positive attitudes and change behaviour while future proofing...
Are we losing sight of what the democratisation of healthcare really looks like?
We have a core responsibility as healthcare communicators to consistently drive for better inclusion, engagement and compliance. What does the ‘democratisation of healthcare’ really look like?...
William Kilgallon
How the Royal Society’s EiR programme can help to drive UK innovation
...